middl
east
respiratori
syndrom
coronaviru
merscov
caus
sever
respiratori
infect
human
specif
elderli
peopl
comorbid
reemerg
lethal
coronavirus
call
intern
collabor
produc
coronaviru
vaccin
still
lack
date
ongo
effort
develop
merscov
vaccin
consid
differ
target
popul
dromedari
camel
human
correl
protect
extend
current
knowledg
mer
vaccin
dromedari
camel
induc
mucos
immun
could
promis
approach
diminish
merscov
transmiss
human
addit
equal
import
develop
vaccin
human
induc
broader
reactiv
variou
coronavirus
prepar
potenti
next
cov
outbreak
nisreen
okba
v
stalin
raj
bart
l
haagman
middl
east
respiratori
syndrom
coronaviru
merscov
caus
sever
respiratori
infect
human
specif
elderli
peopl
comorbid
reemerg
lethal
coronavirus
call
intern
collabor
produc
coronaviru
vaccin
still
lack
date
ongo
effort
develop
merscov
vaccin
consid
differ
target
popul
dromedari
camel
human
correl
protect
extend
current
knowledg
mer
vaccin
dromedari
camel
induc
mucos
immun
could
promis
approach
diminish
merscov
transmiss
human
addit
equal
import
develop
vaccin
human
induc
broader
reactiv
variou
coronavirus
prepar
potenti
next
cov
outbreak
coronavirus
largest
posit
sens
singl
strand
rna
virus
six
human
coronavirus
hcov
date
sever
acut
respiratori
syndrom
sar
cov
middl
east
respiratori
syndrom
mer
cov
prior
sarscov
epidem
cov
known
caus
mild
respiratori
infect
human
sarscov
hand
infect
around
case
caus
sever
respiratori
diseas
fatal
rate
ten
year
later
merscov
emerg
human
popul
also
caus
sever
respiratori
infect
contrast
sarscov
epidem
contain
within
one
year
merscov
still
continu
caus
outbreak
increas
geograph
distribut
four
year
first
identif
march
case
countri
report
death
account
case
fatal
rate
http
wwwwhointemergenciesmerscoven
like
sarscov
merscov
emerg
result
zoonot
introduct
human
popul
despit
close
genom
similar
bat
coronaviru
accumul
serolog
molecular
evid
point
dromedari
camel
probabl
reservoir
merscov
pose
continu
risk
viru
spillov
peopl
contact
camel
work
slaughter
hous
anim
farm
evidenc
presenc
merscov
antibodi
sera
individu
nosocomi
transmiss
howev
account
major
merscov
case
report
outbreak
although
substanti
part
infect
occur
result
unrecogn
asymptomat
mild
ill
thu
addit
camel
contact
highlyatrisk
group
healthcar
worker
patient
household
contact
consid
ongo
merscov
outbreak
crucial
develop
intervent
measur
among
vaccin
play
import
role
despit
fact
emerg
merscov
sarscov
dramat
chang
way
view
cov
licens
cov
vaccin
therapeut
drug
avail
date
cornerston
ration
vaccin
design
defin
determin
immun
protect
accumul
data
studi
done
far
merscov
coronavirus
reveal
combin
virusspecif
humor
cellular
immun
respons
requir
full
protect
coronavirus
especi
neutral
antibodi
consid
key
player
protect
immun
cov
neutral
monoclon
antibodi
mab
reduc
viral
load
merscov
receptortransduc
mice
rabbit
macaqu
similarli
convalesc
camel
sera
increas
viru
clearanc
decreas
lung
patholog
outcom
mice
efficaci
directli
proport
antimerscovneutr
antibodi
nab
titer
also
polyclon
sera
produc
transchromosom
bovin
protect
mice
merscov
challeng
evid
protect
role
antibodi
also
come
recent
studi
analyz
immun
respons
patient
surviv
succumb
merscov
although
neutral
antibodi
weakli
invers
correl
viral
load
serum
antibodi
respons
higher
survivor
compar
fatal
case
viral
rna
elimin
lung
administr
convalesc
sera
howev
lead
signific
reduct
viral
load
presenc
mucos
iga
ab
hand
found
influenc
infecti
viru
isol
besid
humor
immun
cellular
immun
respons
also
consid
play
crucial
role
protect
coronavirus
bcell
defici
mice
abl
clear
merscov
lack
tcell
fail
elimin
viru
point
crucial
role
tcell
viral
clearanc
support
observ
tcell
abl
protect
age
mice
sarscov
infect
fact
reduc
tcell
count
associ
enhanc
diseas
sever
sar
patient
along
studi
data
highlight
import
tcell
viru
clearanc
protect
merscov
sarscov
also
noteworthi
mention
neither
antibodi
memori
b
cell
detect
postinfect
sarscovspecif
memori
tcell
despit
low
frequenc
persist
year
postrecoveri
nonetheless
protect
capac
memori
respons
known
henc
take
account
wane
virusspecif
humor
respons
gener
longliv
memori
cell
respons
vaccin
could
favor
proper
band
tcell
immun
respons
requir
effici
protect
vaccin
target
induct
moment
lack
inform
concern
longev
anamnest
immun
respons
follow
merscov
infect
except
recent
studi
show
antibodi
respons
albeit
reduc
persist
month
postinfect
role
immun
respons
protect
also
line
observ
increas
fatal
among
age
popul
follow
merscov
infect
retrospect
studi
merscov
patient
saudia
arabia
south
korea
found
signific
correl
old
age
mortal
pattern
also
report
respiratori
virus
sarscov
influenza
viru
like
caus
immunosenesc
failur
produc
protect
immun
respons
new
pathogen
elderli
due
impair
antigen
present
alter
function
tlr
reduc
b
cell
repertoir
agerel
increas
mortal
also
report
sarscov
laboratoryinfect
anim
mice
nonhuman
primat
nhp
associ
low
neutral
antibodi
poor
tcell
respons
sever
factor
play
role
tcell
activ
also
found
dysregul
agerel
manner
agerel
increas
phospholipas
group
iid
pla
prostaglandind
lung
contribut
diminish
tcell
respons
sever
lung
damag
diminish
respiratori
dendrit
cell
dc
migrat
likewis
adopt
transfer
tcell
mice
enhanc
viral
clearanc
surviv
highlight
contribut
reduc
tcell
respons
sever
diseas
outcom
observ
also
highlight
need
effect
prevent
measur
elderli
sens
induct
potent
airway
tcell
respons
may
crucial
protect
cov
thu
promis
approach
protect
merscovinduc
fatal
enhanc
virusspecif
tissu
airway
resid
memori
tcell
respons
intranas
vaccin
although
merscov
genom
encod
nonstructur
protein
four
structur
protein
spike
envelop
e
membran
nucleocapsid
n
viral
structur
protein
n
show
highest
immunogen
n
protein
induc
tcell
respons
neutral
antibodi
almost
sole
direct
protein
receptor
bind
domain
rbd
major
immunodomin
region
thu
current
merscov
vaccin
candid
mainli
employ
spike
protein
part
gene
code
glycoprotein
merscov
vaccin
candid
develop
use
wide
varieti
platform
includ
whole
viru
vaccin
vectoredviru
vaccin
dna
vaccin
tabl
proteinbas
vaccin
tabl
although
live
attenu
vaccin
produc
robust
immun
respons
pose
risk
revers
virul
inactiv
viru
vaccin
may
caus
harm
due
incomplet
attenu
capac
induc
lung
immunopatholog
viralvectorbas
vaccin
hand
provid
safer
altern
develop
use
modifi
vaccinia
viru
ankara
mva
adenoviru
adv
measl
viru
mev
rabi
viru
rabv
venezuelan
equin
enceph
replicon
vrp
express
protein
addit
vrp
express
n
protein
also
develop
major
hurdl
face
viralvectorbas
platform
preexist
immun
host
potenti
impair
vaccin
efficaci
howev
prevent
use
viru
strain
circul
target
popul
immun
strategi
involv
heterolog
primeboost
immun
exampl
mva
adv
although
plasmid
dna
vaccin
consid
low
immunogenicti
human
current
version
develop
seem
induc
potent
immun
respons
dnabas
vaccin
direct
induc
anti
respons
also
shown
exert
protect
nhp
noteworthi
mention
middl
east
respiratori
syndrom
coronaviru
vaccin
current
statu
novel
approach
okba
raj
haagman
mice
transduc
adenovir
vector
alum
aluminum
hydroxid
e
envelop
protein
human
dipeptidyl
peptidas
im
intramuscular
intranas
matrix
protein
merscov
middl
east
respiratori
syndrom
coronaviru
nab
neutral
antibodi
nd
done
nhp
nonhuman
primat
rntd
recombin
ntermin
domain
rbd
receptorbind
domain
rrbd
recombin
rbd
rbdfc
rbd
fuse
antibodi
crystalliz
fragment
human
igg
spike
protein
domain
spike
protein
amino
acid
residu
protein
peptid
coupl
keyhol
limpet
haemocyanin
sc
subcutan
vlp
viruslik
particl
im
alumcpg
odn
produc
higher
neutral
antibodi
respons
sc
ifacpg
odn
b
test
highest
nab
titer
although
produc
equal
igg
respons
c
produc
highest
immunogen
low
dose
antigen
compar
mg
antigen
suffici
produc
humor
cellular
immun
respons
similar
higher
dose
mg
mg
poli
c
vaccin
induc
stronger
system
cellular
respons
higher
local
immun
respons
mice
lung
iga
neutral
antibodi
titer
sc
montanid
vaccin
combin
dna
recombin
protein
heterolog
primeboost
immun
strategi
induc
higher
immun
respons
nab
compar
compon
alon
addit
proteinbas
vaccin
develop
variou
platform
viruslik
particl
vlp
nanoparticl
peptidebas
subunit
vaccin
direct
variou
region
spike
protein
ntermin
domain
rbd
vaccin
highest
safeti
profil
among
vaccin
platform
confer
variabl
degre
immunogen
need
adjust
dose
adjuv
site
administr
get
optim
protect
respons
adjuv
influenc
type
magnitud
immun
respons
produc
vaccin
thu
dose
use
addit
rout
administr
determin
factor
type
vaccineinduc
immun
respons
produc
host
intranas
vaccin
sarsn
produc
protect
airway
tcell
respons
sarscov
mice
subcutan
sc
vaccin
induc
system
tcell
respons
likewis
vaccin
mersrbd
induc
significantli
higher
neutral
iga
antibodi
respons
mice
airway
compar
sc
vaccin
import
mucos
immun
airway
memori
tcell
respons
crucial
player
protect
respiratori
virus
sinc
area
first
encount
viru
therefor
along
select
antigen
vaccin
rout
vaccin
adjuv
key
player
neglect
vaccin
design
spike
protein
specif
domain
highli
diverg
among
differ
cov
neutral
antibodi
provid
homotyp
protect
thu
far
variabl
amino
acid
sequenc
spike
protein
observ
among
merscov
strain
low
circul
merscov
strain
show
signific
variat
serolog
reactiv
impli
develop
vaccin
effect
one
strain
like
protect
circul
strain
anoth
risk
pose
develop
antibodi
escap
variant
still
present
although
like
happen
mutat
two
epitop
may
requir
mutant
develop
may
reduc
viral
fit
rbd
consid
ideal
vaccin
candid
merscov
spike
domain
n
protein
conserv
thu
adapt
immun
respons
direct
protein
potenti
lay
basi
broadli
act
coronaviru
vaccin
howev
evid
cross
reactiv
immun
respons
differ
cov
limit
studi
convalesc
sarscov
patient
sera
weakli
neutral
merscov
sarss
reactiv
antisera
show
low
level
neutral
merscov
extrarbd
epitop
could
respons
effect
neutral
epitop
identifi
region
protein
may
immunodomin
rbd
epitop
could
provid
rational
develop
cross
protect
cov
epitopefocus
vaccin
recent
studi
also
demonstr
potenti
role
adapt
respons
n
protein
protect
merscov
infect
vaccin
candid
produc
protect
tcell
respons
merscov
challeng
also
partial
protect
sarscov
moreov
infect
mice
sarscov
reduc
merscov
titer
day
pi
upon
challeng
suggest
develop
cross
reactiv
tcell
respons
thu
map
focus
immun
respons
toward
critic
neutral
tcell
epitop
could
subdomin
may
provid
way
induc
immun
respons
broader
activ
differ
cov
immun
focus
may
also
benefici
gener
robust
virusspecif
immun
respons
vaccin
prepar
epitop
normal
hidden
full
length
protein
structur
get
expos
epitop
could
immunodomin
neg
contribut
overal
neutral
capac
produc
vaccin
also
hold
true
nonneutr
immunodomin
epitop
vaccin
induc
slightli
higher
neutral
whole
ectodomainbas
one
addit
rbd
induc
higher
neutral
antibodi
compar
subunit
vaccin
shorter
region
rbd
induc
even
higher
neutral
respons
indic
addit
region
induc
nonneutr
antibodi
may
contribut
neg
overal
neutral
respons
produc
addit
antibodydepend
enhanc
viral
infect
nonneutr
antibodi
despit
report
far
merscov
need
also
taken
consider
develop
coronaviru
vaccin
one
approach
enhanc
efficaci
subunit
vaccin
mask
negativelycontribut
epitop
glycosyl
approach
immunefocus
epitopebas
vaccin
aim
narrow
immun
respons
target
critic
benefici
epitop
produc
stronger
protect
respons
prerequisit
reach
goal
map
epitop
target
immun
system
identifi
biolog
role
neutral
nonneutr
infect
enhanc
contain
tcell
epitop
achiev
analyz
activ
fine
specif
convalesc
patient
sera
infect
anim
polyclon
sera
monoclon
antibodi
anim
human
pbmc
subsequ
predict
epitop
also
provid
basi
potenti
vaccin
candid
produc
nanoparticl
vlp
character
immun
respons
induc
vaccin
candid
evalu
anim
model
may
util
optim
vaccin
efficaci
figur
epitopefocus
vaccin
approach
may
allow
target
less
immunodomin
band
tcell
epitop
broader
protect
avoid
elicit
immun
respons
epitop
play
role
protect
neg
harm
role
addit
better
target
protect
immunodomin
epitop
combin
epitop
band
tcell
epitop
target
differ
viral
protein
could
use
produc
broader
stronger
protect
immun
respons
strainspecif
univers
cov
vaccin
next
choic
merscov
vaccin
candid
also
import
take
account
target
popul
need
protect
vaccin
popul
risk
merscov
infect
includ
camel
contact
healthcar
worker
patient
contact
latter
two
group
could
benefit
rapid
onset
immun
though
passiv
immun
use
mab
convalesc
sera
provid
given
time
anoth
altern
strategi
shortterm
protect
use
vaccin
capabl
rapidli
induc
high
titer
neutral
antibodi
provid
shortterm
immun
benefici
protect
highlyatrisk
group
new
case
identifi
prevent
outbreak
prevent
viru
infect
primari
case
vaccin
dromedari
camel
may
also
consid
far
among
avail
vaccin
candid
two
test
dromedari
camel
mva
dnabas
vaccin
induc
neutral
antibodi
two
three
camel
test
far
test
efficaci
candid
mva
viralvectorbas
vaccin
induc
system
neutral
antibodi
mucos
immun
confer
protect
merscov
challeng
reduc
viru
shed
vaccin
camel
therefor
vaccin
candid
may
provid
mean
prevent
zoonot
transmiss
viru
human
popul
camel
contact
healthcar
worker
endem
area
continu
risk
merscov
infect
either
infect
camel
patient
respect
would
benefici
induc
longerterm
mucos
protect
could
reward
approach
stop
merscov
outbreak
still
worthwhil
develop
platform
vaccin
aim
induc
broad
protect
differ
relat
cov
could
potenti
caus
futur
outbreak
learn
previou
epidem
issu
list
prioriti
pathogen
pose
risk
human
popul
requir
urgent
research
develop
r
intervent
measur
among
merscov
highli
pathogen
cov
high
prioriti
lack
intervent
measur
along
increas
geograph
area
ongo
mer
epitopebas
vaccin
design
follow
viru
infect
potenti
protect
band
tcell
epitop
map
peptid
protein
contain
promis
epitop
produc
formul
use
suitabl
platform
exampl
nanoparticl
test
immunogen
efficaci
anim
follw
sever
cycl
test
optim
final
vaccin
suitabl
human
use
may
produc
cov
case
rais
worri
futur
occurr
larger
epidem
result
viru
adapt
human
popul
effici
humanto
human
transmiss
develop
merscov
cov
vaccin
thu
need
proactiv
collabor
effort
research
fill
knowledg
gap
market
stakehold
provid
fund
costli
process
latter
insuffici
andor
unsustain
therefor
hinder
develop
even
promis
candid
initi
aim
acceler
vaccin
r
process
provid
sustain
fund
prepar
futur
epidem
world
econom
forum
launch
coalit
epidem
prepared
innov
cepi
cepi
intern
nonprofit
associ
aim
remov
barrier
face
vaccin
develop
epidem
infect
get
readi
futur
epidem
includ
merscov
howev
still
face
number
challeng
despit
fact
variou
promis
merscov
vaccin
candid
current
avail
lack
anim
model
mimick
diseas
human
vaccin
platform
test
prior
human
use
need
take
account
popul
target
vaccin
camel
camel
handler
relev
one
lack
full
understand
pathogenesi
immun
respons
viru
human
camel
crucial
vaccin
develop
also
need
invest
addit
longev
immun
respons
postvaccin
evalu
vaccin
candid
import
vaccin
scheme
develop
choic
best
candid
develop
lastli
vaccin
candid
develop
highli
variabl
spike
protein
thu
may
abl
provid
protect
cov
strain
evolv
futur
target
vaccin
approach
aim
conserv
epitop
consid
develop
broadlyact
cov
vaccin
given
propens
cov
jump
speci
barrier
current
effort
develop
merscov
vaccin
may
also
benefit
prepar
potenti
novel
cov
may
emerg
futur
